On Wednesday, Mirum Pharmaceuticals Inc (MIRM.O) said its drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder called Alagille syndrome (ALGS). Chief Executive Officer Chris Peetz said "(Itching) is really devastating for children and families dealing with this disease